{
  "kind": "all",
  "value": "all",
  "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations",
  "filters": {
    "documentKinds": [],
    "sourceTypes": [],
    "orientations": []
  },
  "total": 319975,
  "page": 7549,
  "pageSize": 30,
  "pageCount": 10666,
  "rows": [
    {
      "docId": "019de076-b515-770b-a5e9-c449fc01e3f7",
      "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4",
      "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides",
      "authorId": "neurobo-pharmaceuticals",
      "authorName": "NeuroBo Pharmaceuticals",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 13,
      "slideType": "product_demo",
      "function": "present_solution",
      "notes": "Includes study design details for a multicenter, randomized, double-blind, placebo-controlled trial.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/13",
      "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7",
      "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-13",
      "loopMatches": [
        {
          "to": 24,
          "from": 4,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e",
          "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)",
          "position": 1,
          "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.6,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 14,
          "from": 7,
          "beatId": "fc2a383c-968e-4c6a-836f-347c2e1bb09a",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Solution",
          "beatSlug": "sequoia-pitch-solution",
          "evidence": "Slides 7-14 detail the solution, including DA-1241 and its competitive differentiation",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b515-770b-a5e9-c449fc01e3f7",
      "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4",
      "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides",
      "authorId": "neurobo-pharmaceuticals",
      "authorName": "NeuroBo Pharmaceuticals",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 14,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a diagram to map the drug's mechanism of action to specific biological effects in the liver, pancreas, and immune system.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/14",
      "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7",
      "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-14",
      "loopMatches": [
        {
          "to": 24,
          "from": 4,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e",
          "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)",
          "position": 1,
          "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.6,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 14,
          "from": 7,
          "beatId": "fc2a383c-968e-4c6a-836f-347c2e1bb09a",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Solution",
          "beatSlug": "sequoia-pitch-solution",
          "evidence": "Slides 7-14 detail the solution, including DA-1241 and its competitive differentiation",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b515-770b-a5e9-c449fc01e3f7",
      "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4",
      "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides",
      "authorId": "neurobo-pharmaceuticals",
      "authorName": "NeuroBo Pharmaceuticals",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 15,
      "slideType": "cover",
      "function": "front_matter",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/15",
      "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7",
      "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-15",
      "loopMatches": [
        {
          "to": 24,
          "from": 4,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e",
          "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)",
          "position": 1,
          "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.6,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 20,
          "from": 15,
          "beatId": "3fbd2aa2-3e57-4d4f-b65f-ea90e59c9f1a",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Market Size",
          "beatSlug": "sequoia-pitch-market-size",
          "evidence": "Slides 15-20 discuss the therapeutic potential of DA-1726 in obesity",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b515-770b-a5e9-c449fc01e3f7",
      "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4",
      "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides",
      "authorId": "neurobo-pharmaceuticals",
      "authorName": "NeuroBo Pharmaceuticals",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 16,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The table highlights DA-1726's dual agonist mechanism (GLP-1R/GCGR) as a key differentiator against standard GLP-1 agonists.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/16",
      "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7",
      "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-16",
      "loopMatches": [
        {
          "to": 24,
          "from": 4,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e",
          "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)",
          "position": 1,
          "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.6,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 20,
          "from": 15,
          "beatId": "3fbd2aa2-3e57-4d4f-b65f-ea90e59c9f1a",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Market Size",
          "beatSlug": "sequoia-pitch-market-size",
          "evidence": "Slides 15-20 discuss the therapeutic potential of DA-1726 in obesity",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b515-770b-a5e9-c449fc01e3f7",
      "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4",
      "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides",
      "authorId": "neurobo-pharmaceuticals",
      "authorName": "NeuroBo Pharmaceuticals",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 17,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a hub-and-spoke diagram to illustrate the systemic effects of the hormone.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/17",
      "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7",
      "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-17",
      "loopMatches": [
        {
          "to": 24,
          "from": 4,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e",
          "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)",
          "position": 1,
          "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.6,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 20,
          "from": 15,
          "beatId": "3fbd2aa2-3e57-4d4f-b65f-ea90e59c9f1a",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Market Size",
          "beatSlug": "sequoia-pitch-market-size",
          "evidence": "Slides 15-20 discuss the therapeutic potential of DA-1726 in obesity",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b515-770b-a5e9-c449fc01e3f7",
      "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4",
      "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides",
      "authorId": "neurobo-pharmaceuticals",
      "authorName": "NeuroBo Pharmaceuticals",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 18,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses preclinical data to demonstrate efficacy superiority over a market-leading GLP-1 agonist.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/18",
      "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7",
      "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-18",
      "loopMatches": [
        {
          "to": 24,
          "from": 4,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e",
          "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)",
          "position": 1,
          "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.6,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 20,
          "from": 15,
          "beatId": "3fbd2aa2-3e57-4d4f-b65f-ea90e59c9f1a",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Market Size",
          "beatSlug": "sequoia-pitch-market-size",
          "evidence": "Slides 15-20 discuss the therapeutic potential of DA-1726 in obesity",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b515-770b-a5e9-c449fc01e3f7",
      "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4",
      "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides",
      "authorId": "neurobo-pharmaceuticals",
      "authorName": "NeuroBo Pharmaceuticals",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 19,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses three distinct chart types to demonstrate efficacy and metabolic impact.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/19",
      "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7",
      "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-19",
      "loopMatches": [
        {
          "to": 24,
          "from": 4,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e",
          "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)",
          "position": 1,
          "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.6,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 20,
          "from": 15,
          "beatId": "3fbd2aa2-3e57-4d4f-b65f-ea90e59c9f1a",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Market Size",
          "beatSlug": "sequoia-pitch-market-size",
          "evidence": "Slides 15-20 discuss the therapeutic potential of DA-1726 in obesity",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b515-770b-a5e9-c449fc01e3f7",
      "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4",
      "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides",
      "authorId": "neurobo-pharmaceuticals",
      "authorName": "NeuroBo Pharmaceuticals",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 20,
      "slideType": "appendix_methodology",
      "function": "present_framework",
      "notes": "Includes definitions for MAD, SAD, PK, PD, FPFV, and LPLV.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/20",
      "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7",
      "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-20",
      "loopMatches": [
        {
          "to": 24,
          "from": 4,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e",
          "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)",
          "position": 1,
          "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.6,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 20,
          "from": 15,
          "beatId": "3fbd2aa2-3e57-4d4f-b65f-ea90e59c9f1a",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Market Size",
          "beatSlug": "sequoia-pitch-market-size",
          "evidence": "Slides 15-20 discuss the therapeutic potential of DA-1726 in obesity",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b515-770b-a5e9-c449fc01e3f7",
      "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4",
      "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides",
      "authorId": "neurobo-pharmaceuticals",
      "authorName": "NeuroBo Pharmaceuticals",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 21,
      "slideType": "section_divider",
      "function": "transition",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/21",
      "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7",
      "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-21",
      "loopMatches": [
        {
          "to": 24,
          "from": 4,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e",
          "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)",
          "position": 1,
          "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.6,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b515-770b-a5e9-c449fc01e3f7",
      "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4",
      "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides",
      "authorId": "neurobo-pharmaceuticals",
      "authorName": "NeuroBo Pharmaceuticals",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 22,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "Includes footnotes regarding anti-dilution provisions and reverse stock split/warrant conversion context.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/22",
      "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7",
      "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-22",
      "loopMatches": [
        {
          "to": 24,
          "from": 4,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e",
          "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)",
          "position": 1,
          "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.6,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b515-770b-a5e9-c449fc01e3f7",
      "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4",
      "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides",
      "authorId": "neurobo-pharmaceuticals",
      "authorName": "NeuroBo Pharmaceuticals",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 23,
      "slideType": "section_divider",
      "function": "transition",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/23",
      "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7",
      "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-23",
      "loopMatches": [
        {
          "to": 24,
          "from": 4,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e",
          "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)",
          "position": 1,
          "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.6,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b515-770b-a5e9-c449fc01e3f7",
      "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4",
      "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides",
      "authorId": "neurobo-pharmaceuticals",
      "authorName": "NeuroBo Pharmaceuticals",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 24,
      "slideType": "executive_summary",
      "function": "summarize",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/24",
      "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7",
      "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-24",
      "loopMatches": [
        {
          "to": 24,
          "from": 4,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e",
          "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)",
          "position": 1,
          "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.6,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b515-770b-a5e9-c449fc01e3f7",
      "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4",
      "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides",
      "authorId": "neurobo-pharmaceuticals",
      "authorName": "NeuroBo Pharmaceuticals",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 25,
      "slideType": "closing_ask",
      "function": "state_next_steps",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/25",
      "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7",
      "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-25",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b5af-740f-a5f5-cc716fe64761",
      "docSlug": "e5f34198aff4080f2687fe569caff4c0",
      "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
      "authorId": "neurosense-therapeutics",
      "authorName": "NeuroSense Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 1,
      "slideType": "cover",
      "function": "front_matter",
      "notes": "Features a 3D rendering of a synapse.",
      "imagePath": "https://imgproxy.kitesheet.com/tRpvqQASDG7X-8yxKqkdicVPWxlRm4jKMmB8JKZSIt4/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9lNWYzNDE5OGFmZjQwODBmMjY4N2ZlNTY5Y2FmZjRjMC9wMDAxLmpwZw",
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/1",
      "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761",
      "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-1",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": "https://imgproxy.kitesheet.com/Apf-gINbshmBzKa3woYv3CPZDKMPlglKvL6JkpuYE8Y/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9lNWYzNDE5OGFmZjQwODBmMjY4N2ZlNTY5Y2FmZjRjMC9wMDAxLnBuZw",
      "thumbSrc": "https://imgproxy.kitesheet.com/zPZTE95TkBnfQwkg5kOMsow4pwoHy_2IU5OKShLiOJI/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9lNWYzNDE5OGFmZjQwODBmMjY4N2ZlNTY5Y2FmZjRjMC9wMDAxLmpwZw",
      "thumbSrcAlt": "https://imgproxy.kitesheet.com/aoRssYLEqGaEx5M0N3qAbNq9IyOplN_qOrTO5y0dmqw/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9lNWYzNDE5OGFmZjQwODBmMjY4N2ZlNTY5Y2FmZjRjMC9wMDAxLnBuZw"
    },
    {
      "docId": "019de076-b5af-740f-a5f5-cc716fe64761",
      "docSlug": "e5f34198aff4080f2687fe569caff4c0",
      "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
      "authorId": "neurosense-therapeutics",
      "authorName": "NeuroSense Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 2,
      "slideType": "appendix_disclosure",
      "function": "other",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/2",
      "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761",
      "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-2",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b5af-740f-a5f5-cc716fe64761",
      "docSlug": "e5f34198aff4080f2687fe569caff4c0",
      "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
      "authorId": "neurosense-therapeutics",
      "authorName": "NeuroSense Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 3,
      "slideType": "executive_summary",
      "function": "summarize",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/3",
      "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761",
      "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-3",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b5af-740f-a5f5-cc716fe64761",
      "docSlug": "e5f34198aff4080f2687fe569caff4c0",
      "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
      "authorId": "neurosense-therapeutics",
      "authorName": "NeuroSense Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 4,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "The slide uses a standard pharmaceutical pipeline visualization (Discovery to NDA).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/4",
      "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761",
      "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-4",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b5af-740f-a5f5-cc716fe64761",
      "docSlug": "e5f34198aff4080f2687fe569caff4c0",
      "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
      "authorId": "neurosense-therapeutics",
      "authorName": "NeuroSense Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 5,
      "slideType": "problem_statement",
      "function": "frame_problem",
      "notes": "Includes a personal testimonial/case study image of a patient (Shay) to humanize the disease.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/5",
      "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761",
      "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-5",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 5,
          "from": 5,
          "beatId": "07446762-8c93-42f3-9372-d09450c844ce",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Problem",
          "beatSlug": "problem-agitate-solution-problem-identify-pain",
          "evidence": "The document identifies ALS as a debilitating disease with limited treatment options (p5).",
          "position": 0,
          "confidence": 0.8,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b5af-740f-a5f5-cc716fe64761",
      "docSlug": "e5f34198aff4080f2687fe569caff4c0",
      "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
      "authorId": "neurosense-therapeutics",
      "authorName": "NeuroSense Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 6,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a biological mechanism-of-action illustration to show how the drug components interact with specific cellular stressors.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/6",
      "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761",
      "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-6",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 17,
          "from": 6,
          "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b5af-740f-a5f5-cc716fe64761",
      "docSlug": "e5f34198aff4080f2687fe569caff4c0",
      "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
      "authorId": "neurosense-therapeutics",
      "authorName": "NeuroSense Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 7,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a combination of a biological mechanism diagram and a pharmacokinetic line chart to prove efficacy.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/7",
      "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761",
      "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-7",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 17,
          "from": 6,
          "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b5af-740f-a5f5-cc716fe64761",
      "docSlug": "e5f34198aff4080f2687fe569caff4c0",
      "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
      "authorId": "neurosense-therapeutics",
      "authorName": "NeuroSense Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 8,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Includes a process diagram for iPSC generation and two charts: a survival curve and a hazard ratio bar chart.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/8",
      "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761",
      "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-8",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 17,
          "from": 6,
          "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b5af-740f-a5f5-cc716fe64761",
      "docSlug": "e5f34198aff4080f2687fe569caff4c0",
      "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
      "authorId": "neurosense-therapeutics",
      "authorName": "NeuroSense Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 9,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The chart demonstrates that PrimeC aligns the peak concentrations of two different drugs, which is the core value proposition of their formulation technology.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/9",
      "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761",
      "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-9",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 17,
          "from": 6,
          "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b5af-740f-a5f5-cc716fe64761",
      "docSlug": "e5f34198aff4080f2687fe569caff4c0",
      "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
      "authorId": "neurosense-therapeutics",
      "authorName": "NeuroSense Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 10,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Study identifier NST002, 15 patients, open-label, intermediate formulation.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/10",
      "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761",
      "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-10",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 17,
          "from": 6,
          "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b5af-740f-a5f5-cc716fe64761",
      "docSlug": "e5f34198aff4080f2687fe569caff4c0",
      "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
      "authorId": "neurosense-therapeutics",
      "authorName": "NeuroSense Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 11,
      "slideType": "appendix_methodology",
      "function": "plan_implementation",
      "notes": "Includes details on screen failures and co-treatment with Riluzole.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/11",
      "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761",
      "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-11",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 17,
          "from": 6,
          "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b5af-740f-a5f5-cc716fe64761",
      "docSlug": "e5f34198aff4080f2687fe569caff4c0",
      "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
      "authorId": "neurosense-therapeutics",
      "authorName": "NeuroSense Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 12,
      "slideType": "appendix_methodology",
      "function": "present_framework",
      "notes": "Uses numbered icons for primary/secondary and a lightbulb icon for exploratory.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/12",
      "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761",
      "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-12",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 17,
          "from": 6,
          "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b5af-740f-a5f5-cc716fe64761",
      "docSlug": "e5f34198aff4080f2687fe569caff4c0",
      "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
      "authorId": "neurosense-therapeutics",
      "authorName": "NeuroSense Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 13,
      "slideType": "appendix_methodology",
      "function": "analyze_data",
      "notes": "Includes a footnote citation for the methodology definitions.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/13",
      "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761",
      "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-13",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 17,
          "from": 6,
          "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b5af-740f-a5f5-cc716fe64761",
      "docSlug": "e5f34198aff4080f2687fe569caff4c0",
      "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
      "authorId": "neurosense-therapeutics",
      "authorName": "NeuroSense Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 14,
      "slideType": "appendix_methodology",
      "function": "other",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/14",
      "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761",
      "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-14",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 17,
          "from": 6,
          "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b5af-740f-a5f5-cc716fe64761",
      "docSlug": "e5f34198aff4080f2687fe569caff4c0",
      "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
      "authorId": "neurosense-therapeutics",
      "authorName": "NeuroSense Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 15,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "The slide shows baseline characteristics for a clinical trial, confirming that the treatment and placebo groups are well-matched.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/15",
      "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761",
      "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-15",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 17,
          "from": 6,
          "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b5af-740f-a5f5-cc716fe64761",
      "docSlug": "e5f34198aff4080f2687fe569caff4c0",
      "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
      "authorId": "neurosense-therapeutics",
      "authorName": "NeuroSense Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 16,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The table displays percentages for various categories of adverse events (AEs) and treatment-emergent adverse events (TEAEs).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/16",
      "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761",
      "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-16",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 17,
          "from": 6,
          "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-b5af-740f-a5f5-cc716fe64761",
      "docSlug": "e5f34198aff4080f2687fe569caff4c0",
      "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
      "authorId": "neurosense-therapeutics",
      "authorName": "NeuroSense Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 17,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The slide highlights a statistically significant 37.4% reduction in disease progression for the Per Protocol population, while noting a 29% reduction (p=0.12) for the ITT population in the footer.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/17",
      "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761",
      "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-17",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 17,
          "from": 6,
          "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    }
  ]
}